



Published in final edited form as:

Cell. 2016 February 25; 164(5): 1015–1030. doi:10.1016/j.cell.2016.01.009.

## TGF- $\beta$ Tumor Suppression Through A Lethal EMT

Charles J. David<sup>1</sup>, Yun-Han Huang<sup>1</sup>, Mo Chen<sup>3</sup>, Jie Su<sup>1</sup>, Yilong Zou<sup>1</sup>, Nabeel Bardeesy<sup>4</sup>, Christine A. Iacobuzio-Donahue<sup>2</sup>, and Joan Massagué<sup>1,5</sup>

<sup>1</sup>Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York, 10065 USA

<sup>2</sup>Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, 10065 USA

<sup>3</sup>The Rockefeller University, New York, New York, 10065 USA

<sup>4</sup>Cancer Center, Massachusetts General Hospital, Boston, MA 02114 USA

### Abstract

TGF- $\beta$  signaling can be pro-tumorigenic or tumor suppressive. We investigated this duality in pancreatic ductal adenocarcinoma (PDA), which, with other gastrointestinal cancers, exhibits frequent inactivation of the TGF- $\beta$  mediator Smad4. We show that TGF- $\beta$  induces an epithelial-mesenchymal transition (EMT), generally considered a pro-tumorigenic event. However, in TGF- $\beta$  sensitive PDA cells, EMT becomes lethal by converting TGF- $\beta$ -induced Sox4 from an enforcer of tumorigenesis into a promoter of apoptosis. This is the result of an EMT-linked remodeling of the cellular transcription factor landscape, including the repression of the gastrointestinal lineage-master regulator Klf5. Klf5 cooperates with Sox4 in oncogenesis and prevents Sox4-induced apoptosis. Smad4 is required for EMT but dispensable for Sox4 induction by TGF- $\beta$ . TGF- $\beta$ -induced Sox4 is thus geared to bolster progenitor identity, while simultaneous Smad4-dependent EMT strips Sox4 of an essential partner in oncogenesis. Our work demonstrates that TGF- $\beta$  tumor suppression functions through an EMT-mediated disruption of a lineage-specific transcriptional network.

### INTRODUCTION

Cancer genes are typically classified as oncogenes or tumor suppressor genes, but a growing number play a dual role and defy this classification (Stepanenko et al., 2013). TGF- $\beta$  and its signaling pathway are a paradigm of duality in cancer (Massagué, 2008). This pathway is a key regulator of pluripotency, proliferation and differentiation of metazoan cells

<sup>5</sup>Correspondence: Joan Massagué, j-massague@ski.mskcc.org.

The authors declare to have no financial interests in connection with this work.

#### AUTHOR CONTRIBUTIONS

C.D. and Y.H. performed most experiments. M.C. performed ChIP-seq experiments, and J.S. performed experiments in organoids. Y.Z. and Y.H. performed bioinformatic analysis. N.B. provided mouse strains. C.I.-D. performed pathology analysis. J.M. conceived and oversaw the project and C.D., Y.H. and J.M., designed the study and wrote the paper.

#### ACCESSION NUMBERS

The raw RNA-seq and ChIP-seq data for this manuscript are available at GEO under the accession number GSE72069.

(Gaarenstroom and Hill, 2014; Massagué, 2012; Oshimori and Fuchs, 2012). The effects of TGF- $\beta$  depend on the cellular context, and this contextual nature is particularly manifest in tumors. TGF- $\beta$  from the inflammatory tumor microenvironment may cause cancer cell apoptosis and tumor suppression (Guasch et al., 2007), or induce an epithelial-mesenchymal transition (EMT) that promotes cancer cell invasion and metastasis (Heldin et al., 2012) and promote cancer stem cell heterogeneity and drug resistance (Oshimori et al., 2015). The mechanistic basis for this duality is a long unsolved question.

TGF- $\beta$  is a major tumor suppressive signal in the gastrointestinal tract and the pancreas (Goggins et al., 1998; Hahn et al., 1996). Acting through membrane receptor kinases, TGF- $\beta$  activates Smad2 and Smad3 transcription factors (TFs), which bind Smad4 as an essential partner for many, though not all TGF- $\beta$  responses (Massagué, 2012). Germline mutations in Smad4 result in familial juvenile polyposis syndrome (Howe et al., 1998), which predisposes to adenocarcinomas of the colon, stomach, and pancreas (Campos et al., 2015). Somatic inactivation of TGF- $\beta$  receptors and Smad proteins are frequent in gastrointestinal carcinomas, with Smad4 inactivation in nearly half of pancreatic ductal adenocarcinomas (PDA) (Hahn et al., 1996).

Ras-mutant premalignant cells are particularly susceptible to TGF- $\beta$ -induced apoptosis (Guasch et al., 2007). In mouse models carrying a *Kras*<sup>G12D</sup> allele in the pancreatic epithelium, loss of *Smad4* accelerates progression to PDA (Bardeesy et al., 2006). Restoration of Smad4 expression in Smad4-defective cancer cells inhibits tumorigenic activity (Duda et al., 2003), and results in apoptosis (Bardeesy et al., 2006; Ramachandra et al., 2002). Notably, Smad4 is not required for normal development of the pancreatic epithelium (Bardeesy et al., 2006).

Cancer cells avoid the tumor suppressive action of TGF- $\beta$  through inactivation of TGF- $\beta$  receptors or Smad genes, or through selective silencing of apoptotic TGF- $\beta$  effects (Massagué, 2008). Carcinoma cells can undergo a TGF- $\beta$ -induced EMT (Heldin et al., 2012). EMT is a developmental plasticity process involving a loss of epithelial features, like expression of the cell junction molecule E-cadherin, and a gain in mesenchymal features (Thiery et al., 2009). In cancer cells, EMT promotes invasiveness and stem cell-like features (Valastyan and Weinberg, 2011).

Apoptosis and EMT are generally viewed as separate fates for TGF- $\beta$ -stimulated cancer cells, and opposite poles of the duality of TGF- $\beta$  in cancer. TGF- $\beta$  triggers EMT through induction of Snail and Zeb1/2 (Thiery et al., 2009), but little is known about how the TGF- $\beta$  pathway triggers apoptosis (Massagué, 2012). To address this question, we dissected the tumor suppressive action of TGF- $\beta$  in Ras-mutant pancreatic cancer cells. We demonstrate that TGF- $\beta$  induces PDA cells to undergo a Smad4-dependent EMT, and EMT then triggers apoptosis. The mechanism involves a conversion of the TF Sox4 from pro-tumorigenic to pro-apoptotic. This occurs as the result of Snail-mediated repression of Klf5, an essential master regulator of endodermal progenitors. Our results illustrate a paradigm in which TGF- $\beta$  tumor suppressive action revolves around an EMT-associated disruption of a pro-tumorigenic transcriptional network.

## RESULTS

### Smad4-dependent EMT and apoptosis in PDA cells

*Pdx1-Cre; lox-stop-lox (LSL)-Kras<sup>G12D</sup>* mice (KC mice) sustain selective activation of the *Kras<sup>G12D</sup>* oncogene in the pancreatic epithelium and form pancreatic intraepithelial neoplasia (PanIN) lesions that fail to progress (Hingorani et al., 2003). When combined with *Cdkn2a<sup>fl/fl</sup>* and *Smad4<sup>fl/fl</sup>* alleles, the mice rapidly develop well-differentiated PDA with a median survival of under 8 weeks (Bardeesy et al., 2006) (Figure 1A). To investigate the effect of Smad4 signaling in premalignant lesions, we compared KC mice with KC mice bearing *Smad4<sup>fl/fl</sup>* alleles (KSC mice). We used caerulein treatment to induce acute pancreatitis, which results in widespread PanIN formation (Morris et al., 2010), and is accompanied by an inflammatory response that includes recruitment of TGF- $\beta$  secreting cells (Konturek et al., 1998). Three days after caerulein administration, we found a higher rate of apoptosis in the Smad4-wildtype pancreas than in the Smad4-mutant pancreas (Figure 1B), consistent with earlier evidence that the main outcome of tumor-suppressive TGF- $\beta$  signaling is apoptosis (Guasch et al., 2007).

To examine the mechanism of apoptosis, we used mouse PDA cells isolated from KSC; *Cdkn2a<sup>fl/fl</sup>* (KSIC) mice. The cells, having been selected during tumorigenesis in the absence of Smad4 signaling, should be sensitive to the tumor suppressive effect of restored Smad4 expression. We introduced a doxycycline-inducible (TetOn) Smad4 construct into early-passage primary PDA cells, and achieved a Smad4 expression level comparable to the endogenous level in Smad4 wild type cells (Figure S1A). When subcutaneously injected into syngeneic mice, the Smad4-restored (Smad4+) PDA cells had a lower tumor incidence than Smad4-mutant counterparts (Figure S1B). We induced pancreatitis with caerulein, and orthotopically implanted PDA cells. Smad4-mutant PDA cells efficiently formed tumors (4/6 mice), whereas no tumors (0/7 mice) were detected after two months in Smad4(+) cells. The Smad4-mutant orthotopic tumors were histologically indistinguishable from autochthonous tumors formed in KSIC mice (Figure 1C), and presented with occasional liver metastasis, indicating that they retained the biological characteristics of their autochthonous counterparts.

Histologic analysis of the pancreata 3.5 days after injection of GFP-labeled PDA cells (see Figure S1A) revealed little evidence of cell death in injected Smad4-mutant cells but showed membrane blebbing and pyknotic nuclei in injected Smad4+ cells (Figure 1D, see inset), suggesting activation of apoptosis. Of interest, the dead cells were intermingled with cancer cells displaying spindle morphology and loss of E-cadherin staining, consistent with an EMT, while the Smad4-mutant cells retained E-cadherin expression (Figure 1D; Figure S1C). In cells constitutively expressing Smad4, doxycycline-inducible expression of the anti-apoptotic protein Bcl-X<sub>L</sub> reduced cell death and cleaved caspase 3 (CC3) staining when orthotopically injected (Figure S1D,E). Knockdown of the TGF- $\beta$  receptor subunit Tgfr2 reversed the EMT phenotype in Smad4(+) cells (Figure S1F) and rescued tumor formation (Figure S1G) indicating that the phenotype is due to TGF- $\beta$  action.

When cultured under low-mitogen cell suspension conditions, cancer cells form “oncospheres” that are enriched for tumor-initiating cells (Lonardo et al., 2011). Treatment

of PDA oncospheres with TGF- $\beta$  resulted in a Smad4-dependent reduction in growth and a increase in apoptosis (Figures S1H,I). TGF- $\beta$  or the TGF- $\beta$  receptor kinase inhibitor SB505124 (DaCosta Byfield et al., 2004) had no effect on the viability of Smad4+ cells in monolayer culture with serum growth factors (Figure S1J). Serum starvation sensitizes PDA cells to TGF- $\beta$ -induced apoptosis (Bardeesy et al., 2006), and growth factor-activated Akt mediates anti-apoptotic effects through Bcl-X<sub>L</sub> (Chen et al., 1998). Treatment of Smad4-expressing PDA cells with the Akt inhibitor MK2206 (Figure 1E) synergized with TGF- $\beta$  to promote apoptosis, and this effect was inhibited by overexpression of Bcl-X<sub>L</sub> (Figure S1K). These results show that TGF- $\beta$ /Smad4 signaling triggers Akt- and Bcl-X<sub>L</sub>-sensitive apoptosis in Smad4+ PDA cells.

### Smad4-dependent EMT precedes apoptosis in PDA cells

To examine the possibility that EMT precedes apoptosis, we conducted time-lapse imaging of PDA cells for 3 days after the addition of TGF- $\beta$ . Smad4-mutant cells exhibited little cell death throughout this period, and retained epithelial morphology (Supplementary Video 1). In contrast, Smad4+ cells started with epithelial morphology, but within 24 h lost cellular polarity and cell-cell contacts, and assumed a spindle-like appearance. From 24–72 h, most spindle-like cells began to shrink, formed membrane blebs, and dissociated into apoptotic bodies (Supplementary Video 1; Figure 1F). Consistent with this sequence of events, TGF- $\beta$  treatment in Smad4+ cells decreased E-cadherin levels at 18 h, followed by CC3 accumulation (Figure 1G).

We generated organoids from mouse PDA tissues (Boj et al., 2015). Organoids from KSIC tumors were little affected by TGF- $\beta$  addition. In contrast, KIC organoids underwent extensive apoptosis after TGF- $\beta$  addition (Figure 1H), accompanied by a loss of structural integrity and increased CC3 staining (Figure 1I). Peak apoptosis was preceded by a strong increase in the expression of the EMT transcription factor (EMT-TF) Snail (Figure S1L) (Thiery et al., 2009), and by a loss of E-cadherin staining (Figure 1I). CC3-positive cells were invariably E-cadherin negative (Figure S1M).

In tumor cell isolates from mice of multiple genotypes Smad4-mutant cells were uniformly resistant to TGF- $\beta$ -induced EMT, and Smad4 restoration resulted in EMT followed by apoptosis (Figure S1N,O). Smad4-wildtype PDA tumors developing in the KIC model give rise to epithelial cells that undergo apoptosis in response to TGF- $\beta$  (Bardeesy et al., 2006). As with KIC organoids, these lines underwent EMT preceding apoptosis in response to TGF- $\beta$  (Figure S1M, N). The human Smad4-mutant pancreatic cancer cell line BxPC3 was resistant to TGF- $\beta$ -induced EMT and apoptosis, and Smad4 re-expression sensitized these cells to undergo EMT and apoptosis (Figure S1P,Q).

### EMT transcription factors prime cells for TGF- $\beta$ -induced apoptosis

We performed RNA-seq after 90 min and 24 h of TGF- $\beta$  treatment. Snail was prominently induced at the mRNA and protein levels (Figure 2A,B). Smad2/3 ChIP-seq analysis at 90 min post-TGF- $\beta$  treatment showed binding of Smad2/3 to the *Snail* locus in Smad4+ cells but not Smad4-mutant cells (Figure 2C). Zeb1 and Zeb2 are EMT-TFs that respond to TGF- $\beta$  in other cell types (Heldin et al., 2012). Zeb1 was highly expressed in PDA cells

regardless of the Smad4 status, and was only marginally increased by TGF- $\beta$  in Smad4+ cells (Figure 2B). Zeb2 was not detected under any of these conditions (data not shown).

shRNAs targeting *Snail* and *Zeb1* transcripts (Figure S2A,B) blocked TGF- $\beta$ /Smad4-induced E-cadherin downregulation (Figure 2D). Moreover, *Snail* and *Zeb1* depletion in Smad4+ PDA cells suppressed the induction of EMT-like morphological changes (Figure 2E) and apoptosis by TGF- $\beta$  (Figure 2F). When we introduced a TetOn-*Snail* construct into Smad4+ cells, *Snail* overexpression did not induce apoptosis in the absence of TGF- $\beta$ , but synergized with TGF- $\beta$  in the induction of apoptosis (Figure 2G). These results indicate that *Snail* induction by TGF- $\beta$ , together with basal *Zeb1* expression, is necessary but not sufficient to cause apoptosis in PDA cells, and induction of apoptosis must involve an additional TGF- $\beta$  dependent input.

### Snail inhibits pancreatic tumorigenesis in mice

The requirement of *Snail* for TGF- $\beta$ /Smad4-induced apoptosis suggested that *Snail* might inhibit pancreatic tumorigenesis. We crossed mice bearing a conditional allele of *Snail* with KC mice to generate *Pdx1-Cre; LSL-Kras<sup>G12D</sup>; Snail<sup>+/-flox</sup>* (KSnC) and *Pdx1-Cre; LSL-Kras<sup>G12D</sup>; Snail<sup>flox/flox</sup>* (KSnSnC) mice. At 8 weeks, KSnC and KSnSnC pancreata were indistinguishable from their KC littermates (data not shown).

Spontaneous progression to invasive PDAC in KC mice is rare, and when encountered occurs after 12 months of age (Hingorani et al., 2003). Typically, the development of PDA requires the inactivation of tumor suppressors (Aguirre et al., 2003; Hingorani et al., 2005), and develops through progression of increasingly atypical pancreatic intraepithelial neoplasia (PanIN) lesions. Consistent with prior reports, cohorts of KC mice sacrificed at 4–5 months showed various grades of acinar-to-ductal metaplasia (ADM) and pancreatic intraepithelial neoplasia (PanIN) but no invasive PDAC was seen. PanINs were seen at approximately the same frequency in KSnC and KSnSnC mice. By contrast, 7/9 KSnSnC mice had developed multifocal regions of atypical ADM, with confluent and highly disorganized CK19+ cells displaying nuclear atypia, consistent with carcinoma in situ (Figure 2H, S2C). These results suggest that carcinoma in situ arose directly from ADM without progression through a PanIN intermediary. Such regions were not seen in KC mice and occasionally seen in KSnC mice (Table S1). One of the KSnSnC mice, aged 4.75 months, progressed to invasive PDAC, with liver metastases (Figure S2C). These data suggest that *Snail* plays a tumor suppressive role at an early stage in PDA carcinogenesis.

### Sox4 is required for EMT-associated apoptosis

Since apoptosis enhancement by *Snail* overexpression in Smad4-expressing PDA cells required an additional TGF- $\beta$  input, we searched for additional TGF- $\beta$ -induced factors that cooperate with *Snail* to induce cell death. Based on our RNA-seq data, we constructed miR-30 based shRNA libraries (Zuber et al., 2011) targeting the mRNAs induced by TGF- $\beta$  over 90 min in Smad4+ PDA cells (Table S2). These pools were transduced into Smad4+ PDA cells, which were then treated with SB505124 or TGF- $\beta$  for 5 days. ShRNA representation was then determined by deep sequencing (Figure 3A). shRNAs targeting the TGF- $\beta$  receptor subunits *Tgfb $\beta$ 1* and *Tgfb $\beta$ 2*, included as positive controls, were enriched

following cell treatment with TGF- $\beta$  (Figure 3B). *Snai1.1197*, which caused a potent knockdown of *Snai1* and rescue of cell viability (refer to Figure 2F), was among the top 10% of enriched shRNAs in each of two replicates in the screen.

Sox4 scored as a candidate factor required for TGF- $\beta$ -induced apoptosis (Figure 3B). Sox4 (SRY-related HMG box 4) is widely expressed during mouse embryogenesis, and functions in the development of many tissues (Vervoort et al., 2013). After birth, Sox4 expression is restricted to progenitor cells in pancreatic, intestinal, uterine and mammary epithelia, and maintains epithelial progenitor identity in a range of tissues (Doulatov et al., 2013; Ikushima et al., 2009; Zhang et al., 2013b), including pancreatic epithelium (Wilson et al., 2005). Sox4 is upregulated in various types of carcinoma and leukemia (Vervoort et al., 2013).

RNAi-mediated knockdown of Sox4 in Smad4<sup>+</sup> PDA cells abrogated TGF- $\beta$ -mediated apoptosis (Figure 3C) but had little effect on EMT morphology (Figure 3D, Supplementary Video 2) or E-cadherin expression (Figure 3E). Conversely, shRNA-mediated depletion of Snail or Zeb1 had no effect on Sox4 expression (Figure 3F). Sox4, through its regulation of *Ezh2*, was implicated in EMT in mammary epithelial cells (Tiwari et al., 2013b). However, Sox4 knockdown in PDA cells had little effect on *Ezh2* mRNA levels (data not shown). Moreover, *SOX4* mRNA levels show a positive correlation with those of *CDH1* (E-cadherin) in human PDA (Figure 3G), indicating that Sox4 is not a mediator of EMT in this context. In PDA cells, TetOn-driven Sox4 expression triggered extensive apoptosis only after TGF- $\beta$  addition (Figure 3H). These results show that neither Snail nor Sox4 are pro-apoptotic separately, but the simultaneous induction of EMT and Sox4 by TGF- $\beta$  is lethal to PDA cells.

### The Smad4-independent TGF- $\beta$ program and Sox4

The involvement of Sox4 in EMT-associated apoptosis was surprising given its role as a progenitor identity factor in epithelial tissues, including the pancreas. An additional parallel between Sox4 and pancreatic development emerged when we examined the requirement of Smad4 for Sox4 expression. Although Smads 2 and 3 play a key role in the development and patterning of the foregut and pancreas (Wiater and Vale, 2012), Smad4 is dispensable for normal pancreas development (Bardeesy et al., 2006). Notably, Sox4 induction by TGF- $\beta$  was Smad4-independent in all Smad4-mutant mouse lines that we tested (Figure 4A,B and data not shown). Consistent with the Smad4-independent nature of Sox4 induction, IHC staining for Sox4 showed strong nuclear positivity in both Smad4-null and Smad4-restored PDA cells in vivo (Figure 4C).

RNA-seq transcriptomic analysis revealed 165 genes that were differentially expressed > 2-fold after addition of TGF- $\beta$  for 90 min to Smad4<sup>+</sup> PDA cells. Of these responses, 145 were Smad4-dependent (Smad4 WT:mutant fold-change ratio >1.5), including well-known Smad4-dependent genes like *Smad7*, *Interleukin-11*, and *Snai1* (Figure 4D). An additional set, including *Sox4*, *Junb*, *Sgk1* and *Fn1*, were equally induced by TGF- $\beta$  regardless of Smad4 status, with induction occurring over a longer timescale (Figure 4D). Smad2/3 bound similarly to the *Sox4* locus in the presence and the absence of Smad4 by ChIP-seq (Figure 4E). Thus, Sox4 is in a small group of genes whose response to TGF- $\beta$  involves Smad2/3 but is independent of Smad4 (Figure 4F).



## Role of Sox4 in PDA tumor-initiating activity

These observations raised the possibility that Sox4, while pro-apoptotic to PDA cells that undergo a TGF- $\beta$ -induced EMT, may be important for the tumor-initiating capacity of these cells. For an unbiased assessment of this possibility, we screened PDA TFs for their requirement in oncosphere growth. To identify putative master regulators (Lee and Young, 2013), we ranked PDA TFs by RNA abundance and created pooled miR-E shRNA libraries targeting the top 93 TFs (Table S3) (Fellmann et al., 2013; Zuber et al., 2011). We transduced these libraries into Smad4-mutant PDA cells, grew the cells as oncospheres for 18 days, and determined the relative enrichment or depletion of individual shRNAs (Figure 5A). shRNAs targeting *Myc*, a TF required for PDA formation (Saborowski et al., 2014), were strongly depleted from the oncospheres, validating our approach (Figure 5B). *Sox4* shRNAs were also strongly depleted. PDA cells required Sox4 for growth as oncospheres (Figure 5C,D) but not growth in monolayer (Figure 5E). Importantly, Sox4 depletion in PDA cells inhibited tumor formation in both the subcutaneous (Figure 5F) and orthotopic setting (Figure 5G). Cells grown as oncospheres exhibited higher Sox4 levels than cells grown in adherent conditions (Figure 5H). Pretreatment of Smad4-mutant oncospheres with TGF- $\beta$  resulted in increased capacity for secondary oncosphere formation (Figure 5I).

Collectively, the results show that TGF- $\beta$  induces Sox4 expression in PDA cells independently of Smad4, and Sox4 supports tumor-initiating properties of PDA cells, consistent with the role of Sox4 in the epithelial progenitor state. Yet, Sox4 triggers apoptosis in cells that undergo a TGF- $\beta$ /Smad4-induced EMT, implying that EMT switches Sox4 function from pro-tumorigenic in epithelial PDA cells to pro-apoptotic if these cells undergo an EMT (Figure 4F).

## Klf5 as a lineage survival gene that cooperates with Sox4 in PDA

To define the Sox4 transcriptional program in epithelial PDA cells, we performed Sox4 ChIP-seq in these cells and identified approximately 3000 Sox4-bound peaks, including in the established Sox4 target *Nestin* (Figure S6A). Analysis of sequences within the Sox4 peaks revealed enrichment of consensus binding motifs for other TFs (Figure S6B), including the related but often functionally opposed TFs Klf4 and Klf5 (Ghaleb et al., 2005). Interestingly, Klf5 had scored in our PDA oncosphere formation screen as a mediator, whereas Klf4 scored as an inhibitor (Figure 5B). Klf5 enforces epithelial identity (Zhang et al., 2013a), is required for the integrity and oncogenicity of intestinal stem cells (Nakaya et al 2014), and is a lineage survival oncogene in gastric cancer (Chia et al., 2015). Using RNAi, we confirmed the requirement of Klf5 for oncosphere formation by PDA cells (Figure 6A). Knockdown of Klf5 in oncospheres, which express high levels of Sox4 (refer to Figure 5H), resulted in activation of apoptosis (Figure S6C). As with Sox4, Klf5 knockdown strongly inhibited orthotopic tumor formation (Figure 6B).

Nuclear Klf5 staining was absent in the normal pancreas, present in rare cells in ADM lesions, and nearly uniform in neoplastic lesions (Figure S6D), suggesting that pancreatic tumorigenesis involves the expansion of a Klf5+ progenitor pool. Consistent with its high expression the *Klf5* locus is flanked by a super enhancer in PDA cells, as determined by Med1 ChIP-seq (Figure S6E) (Whyte et al., 2013). High, lineage specific expression is a

hallmark of lineage survival oncogenes such as MITF in melanoma (Figure 6C). Similarly, *KLF5* expression in human tumors is lineage restricted, with *KLF5* ranking among the most highly expressed TFs in GI and squamous carcinomas (Figure 6C), tumors that exhibit high rates of loss of TGF- $\beta$  signaling. Lineage survival oncogenes often exhibit genomic amplification (Garraway and Sellers, 2006), and TCGA copy-number data show amplifications of *KLF5* in colorectal, esophageal, stomach and pancreatic carcinomas (data not shown). Taken together, these data suggest that Klf5 functions as a lineage survival gene in pancreatic and other GI cancers.

Genome-wide Sox4 ChIP-seq revealed that approximately 80% of Sox4 peaks were associated with an overlapping Klf5 peak (Figure 6C). These data indicate that Klf5 may be an important determinant of Sox4 function in PDA. Consistent with this, Klf5 knockdown in Smad4-mutant PDA cells was accompanied by increased apoptosis (Figure 6E, S6F), which was further accentuated by TGF- $\beta$  addition. Knockdown of Foxa2, another highly expressed TF, did not promote TGF- $\beta$ -induced apoptosis (Figure 6E). In a reciprocal experiment, enforced expression of Klf5 in Smad4(+) cells prevented TGF- $\beta$ -induced apoptosis (Figure 6F) and E-cadherin downregulation (Figure 6G), and increased the tumorigenic activity of Smad4(+) PDA cells (Figure 6H, S6G). These results suggested that a low Klf5:Sox4 ratio might trigger PDA cell death. Using tandem expression of Sox4 shRNAs with a Klf5 shRNA, we confirmed that Sox4 promotes apoptosis upon Klf5 depletion (Figure 6I), thus linking apoptosis in PDA to an imbalance between Sox4 and Klf5.

### Repression of Klf5 turns Sox4 into a pro-apoptotic TF

EMT-TFs repress the expression of transcription factors that determine the epithelial state (Cicchini et al., 2006). Our RNA-seq data revealed a loss in the expression of 20 abundant PDA TFs during EMT, including Klf5 (Figure S7A). We confirmed the Smad4-dependent downregulation of Klf5 and other endodermal TFs (Figure 7A). In vivo, nuclear Klf5 was expressed in Smad4(−) PDA cells, but was undetectable in Smad4(+) cells with EMT morphology (Figures 7B, S7B). Knockdown of Snail and Zeb1 blunted the downregulation of Klf5 by TGF- $\beta$  (Figure S7C). *KLF5* mRNA levels showed a strong positive correlation with *CDH1* expression in human PDA (Spearman's  $\rho = 0.54$ ; Figure S7D).

The *Klf5* locus showed Smad4-dependent binding of Smad2/3 (Figure S7E), suggesting that TGF- $\beta$ -activated Smads play a direct role in *Klf5* repression in the context of an EMT. A major Smad binding site immediately downstream of Klf5 is centered around two E-boxes (CACCTG), known to serve as binding sites for both Zeb1 and Snail (data not shown) (Burk et al., 2008). An identical region exhibits Zeb1 binding in a ENCODE ChIP-seq dataset from human hepatocellular carcinoma HepG2 cells (Figure S7F) (ENCODE, 2012). Knockdown of either Snail or Zeb1 did not prevent Smad binding to universal TGF- $\beta$ -responsive genes *Smad7* and *Serpine1* (Figure 7C), but eliminated Smad binding at the Klf5-downstream site and at the E-cadherin locus (Figure 7C), a known site of Smad/EMT-TF cooperation (Vincent et al., 2009). These data indicate that Smads induce, then cooperate with EMT-TFs to repress Klf5 and E-cadherin.

To identify Sox4-dependent mediators of apoptosis in the post-EMT context, we performed RNA-seq on Smad4+ cells with and without Sox4 knockdown. After 24 h of TGF- $\beta$



treatment, 1169 genes were induced by TGF- $\beta$ . Of these, 290 showed a >2-fold difference in their TGF- $\beta$  response in Sox4 depleted cells compared to controls. The set of TGF- $\beta$  gene responses that were lost in Sox4-depleted PDA cells included Bim (encoded by *Bcl2l1*) and Bmf (Figure 7D). Bim and Bmf are BH3-only pro-apoptotic proteins, which are sequestered by Bcl-X<sub>L</sub> (Pinon et al., 2008). These observations were consistent with the ability of Bcl-X<sub>L</sub> to blunt TGF- $\beta$ -induced apoptosis in this context (refer to Figures S1C and S1F). We confirmed that the increased expression of Bim and Bmf in response to TGF- $\beta$  in PDA cells requires Sox4 (Figure 7E). Thus, repression of Klf5 by TGF- $\beta$ -induced EMT-TFs switches Sox4 from a pro-tumorigenic enforcer in malignant endodermal progenitors to an inducer of tumor suppressive, pro-apoptotic genes (Figure 7F).

## Discussion

Our results provide a mechanistic basis for the duality of TGF- $\beta$  in pancreatic adenocarcinoma. The mechanism involves a Smad4-dependent EMT that perturbs a pro-tumorigenic transcriptional network, resulting in apoptosis. This perturbation involves the simultaneous activation of conflicting programs: one, involving Sox4, appears geared to reinforce an endodermal progenitor identity of PDA cells, while another, EMT, represses a set of endodermal TFs that would normally partner with Sox4 to establish this progenitor state. Repression of these endodermal factors, most notably Klf5, switches the activity of Sox4 from pro-tumorigenic in the presence of cooperating endodermal TFs to pro-apoptotic in their absence (Figure 7G). These observations reveal a driving force for the accumulation of *SMAD4* mutations in pancreatic cancer and possibly other endoderm-derived carcinomas.

### TGF- $\beta$ control of cellular identity drives lineage-specific tumor suppression

TGF- $\beta$  superfamily members are powerful orchestrators of cell identity changes throughout development, and our results implicate this property in tumor suppression. Pre-neoplastic lesions are dependent on TFs that maintain progenitor populations endemic to the tissue of origin (Garraway and Sellers, 2006). In tumor types most sensitive to TGF- $\beta$ , Klf5 appears central to the identity of these progenitors. Klf5 marks proliferative progenitors in the developing GI tract (Ohnishi et al., 2000). Klf5 deletion in mouse intestinal stem cells results in apoptosis and depletion of Lgr5<sup>+</sup> cells (Nakaya et al., 2014; Nandan et al., 2015), and abrogates tumor formation (Nakaya et al., 2014). *KLF5* displays amplifications or stabilizing mutations (Bialkowska et al., 2014; Chia et al., 2015) and high-level expression restricted to a set of GI and squamous tumor types most prone to genetic inactivation of the TGF- $\beta$  pathway.

Sox4 is associated with stem/progenitor cell properties in many contexts (Doulatov et al., 2013; Ikushima et al., 2009; Zhang et al., 2013b). We show that in PDA cells, Sox4 co-binds the genome with Klf5, and cooperates with Klf5 to establish this progenitor-like state. By repressing endodermal TFs, TGF- $\beta$  drives the lethal collapse of the Sox4-Klf5 network, imposing a cell identity-specific bottleneck. Cells could emerge from this TGF- $\beta$ -imposed bottleneck either by a) losing TGF- $\beta$  signaling components, b) attaining a self-renewing epigenetic state compatible with TGF- $\beta$  signaling, or c) activating signaling pathways that blunt the effects of TGF- $\beta$ . Smad4-wildtype mouse models often give rise to tumors with

loss of E-cadherin and sarcomatoid differentiation (Bardeesy et al., 2006; Rhim et al., 2012); cells derived from these tumors resist death when treated with TGF- $\beta$  (Bardeesy et al., 2006), a likely example of (b). Such tumors are rare in human pancreas cancer (Kane et al., 2014), indicating that different mechanisms of escape from TGF- $\beta$  suppression predominate in human tumors.

### A tumor suppressive EMT

A remarkable finding here is that tumor suppression is coupled to an EMT, a developmental program thought to promote the acquisition of malignant traits in advanced carcinomas (Valastyan and Weinberg, 2011). This coupling occurs through the function of the EMT-TFs Snail and Zeb1, which are induced by, and cooperate with Smad4 to bring about the repression of Klf5. Kras mutations sensitize PDA cells to TGF- $\beta$ -induced EMT (Horiguchi et al., 2009), and sensitize keratinocytes to TGF- $\beta$ -induced apoptosis (Guasch et al., 2007). Taken together, these observations suggest that Kras mutations sensitize incipient carcinoma cells to lethal EMT. Human PDA shows frequent repression-associated methylation of the *ZEB2* promoter, while miR-200a/200b, which suppress *ZEB1* and *ZEB2*, are overexpressed (Li et al., 2010).

Our work highlights a role of EMT in tumor suppression and provides a mechanism for EMT-triggered apoptosis. An association of EMT with apoptosis is not unprecedented. Serum-starved canine kidney epithelial cells undergo EMT followed by cell death in response to TGF- $\beta$  (Peinado et al., 2003). EMT can also precede apoptosis in response to TGF- $\beta$  in murine mammary epithelial cells (Gal et al., 2008; Tiwari et al., 2013a). In the presence of sustained TGF- $\beta$  treatment, the emergence of proliferative cells that survive EMT requires 2–3 weeks (Gal et al., 2008), which is consistent with our findings that lethal EMT imposes a narrow bottleneck on naïve epithelial cells. While the bulk of naïve PDA cells are susceptible to EMT-linked death, EMT-permissive cells can emerge from the TGF- $\beta$ -imposed bottleneck (Bardeesy et al., 2006; Gal et al., 2008; Rhim et al., 2012). Moreover our results indicate that tumorigenicity linked to an EMT is not broadly endowed on incipient carcinoma cells, but is rather a trait that must be selected during carcinoma progression.

### The dual nature of TGF- $\beta$ and core TF regulation

Our results clarify the long unexplained dual role of TGF- $\beta$  in cancer. Despite its clear tumor-suppressive properties, a high level of TGF- $\beta$  signaling in PDA tumors is associated with poor prognosis (Friess et al., 1993; Wagner et al., 1999). Our observation that Sox4 is induced in a Smad4-independent manner provides one potential mechanism by which TGF- $\beta$  may promote aggressiveness in Smad4-null PDA and could account for the predominance of Smad4 loss over TGF- $\beta$  receptor inactivation in human PDA. Approximately half of PDAC harbor *SMAD4* mutations, but few harbor *TGBFR* mutations (Goggins et al., 1998), underscoring the requirement to bypass Smad4-dependent lethal EMT but not TGF- $\beta$ -mediated tumor-promoting effects. PDA tumors with wild-type *SMAD4* status tend to have fewer metastases (Iacobuzio-Donahue et al., 2009) perhaps reflecting an increased susceptibility of these disseminated cells to suppression by stromal TGF- $\beta$ . Our results that conditional *SNAIL* knockout PDAC retains metastatic competency are consistent with a

recent report that EMT is not always connected with effective metastatic dissemination in PDA (Zheng et al., 2015). Smad4-independent induction of Sox4, a known component of pancreatic progenitors (Wilson et al., 2005), also provides a potential resolution to the apparently paradoxical observation that activin receptor mutant mice develop a severely hypoplastic pancreas, whereas Smad4 is dispensable for normal pancreas development (Bardeesy et al., 2006; Kim et al., 2000).

Sox4 both mirrors and contributes to the context-dependent dual nature of TGF- $\beta$ . Sox4 is an established stem/progenitor factor that functions as a driver of apoptosis in some contexts (Vervoort et al., 2013). We show that the major determinant of context is the cellular repertoire of transcriptional master regulators. Why would a stemness factor be endowed with the ability to induce apoptosis in the absence of appropriate transcriptional partners? We speculate that this property evolved as a mechanism to eliminate stem cells with developmentally untenable TF configurations.

## EXPERIMENTAL PROCEDURES

### Animal studies

All animal experiments were done in accordance with a protocol approved by the MSKCC Institutional Animal Care and Use Committee. All implantations were carried out in FVB mice purchased from the Jackson Laboratory or Harlan Laboratories, aged 4–6 weeks, except orthotopic implantation of Sox4 and Klf5 knockdown cells, which were performed in 6-week-old athymic mice. Mice bearing a Snail flox allele (B6;129S-Snai1tm2Grid/J) were purchased from the Jackson Laboratory, and were crossed with *Pdx1-Cre; LSL-Kras<sup>G12D</sup>* mice in FVB background. Caerulein treatment was performed as described (Morris et al., 2010). Orthotopic injections were performed as described (Rhim et al., 2012), except cells were suspended in 25  $\mu$ l matrigel prior to injection. For Smad4 $^{+/-}$  tumor formation, 3000 cells were injected, for tracking cell fate post-injection, 100,000 cells were injected. For TetOn Smad4 in vivo studies, cells were pretreated with Dox for at least 12 hours prior to injection, and mice were maintained on Dox for the duration of the study. Sox4 and Klf5 KD orthotopic injections were performed with 5000 cells each, without prior caerulein treatment. shRNAs were induced for two days with dox prior to injection. Three-week luciferase signal was normalized to the day 0 value measured in the exposed post-injection pancreas.

### In vitro cell-based assays

For in vitro cleaved Caspase activity measurements, cells were plated in 96-well format at 500 cells/well for 12–24 h prior to treatment with MK2206 (Tocris, 2.5  $\mu$ M), and SB505124 (Sigma, 2.5  $\mu$ M) or TGF- $\beta$  (R&D; 100 pM). Cells were assayed for cleaved Caspase 3/7 activity using CaspaseGlo (Promega) and normalized to cell titer using Cell TiterGlo (Promega). Experiments were performed in triplicate, and analyzed using Student's unpaired t-test. For oncosphere formation assays, 500 cells/well were plated in ultra-low attachment 96 well plates (Corning) in DMEM/F-12 medium supplemented with B-27 serum replacement and 5  $\mu$ g/ml Heparin. Organoids were cultured as described (Boj et al., 2015).

## shRNA screening

Pooled miR-30 and miR-E based shRNA libraries were ordered from custom arrays and cloned into pTRIPZ or SGEP respectively. Libraries were transduced into cells at transduction efficiencies of ~10% to ensure single-copy representation of shRNAs. For TGF- $\beta$  screening, shRNAs were expressed for three days prior to addition of SB505124 or TGF- $\beta$ . For TF screening, cells were expanded for two passages prior to plating in oncosphere conditions. To ensure adequate library representation, in all experiments libraries were represented by a cell number  $(1000 \times \text{library size})$  prior to relevant treatment. Additional procedures were performed as described (Zuber et al., 2011).

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

We thank S. Lowe, A. Lujambio, J. Ahn, R. Grippa, and Q. Xiang for help and advice with shRNA screening. We thank C. Huang for the tandem shRNA vector, K. Xu, M. Overholtzer and S.E. Kim for help with time-lapse videos. This work was supported by NIH grants R01-CA34610 (J.M.) and P30-CA008748 (MSKCC), and MSKCC Translational Research Oncology Training Program (C.D.). Y.H was supported by NIH Medical Scientist Training Program grant T32GM007739 to the Tri-Institutional MD/PhD Program.

## References


- Aguirre AJ, Bardeesy N, Sinha M, Lopez L, Tuveson DA, Horner J, Redston MS, DePinho RA. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. *Genes & development*. 2003; 17:3112–3126. [PubMed: 14681207]
- Bardeesy N, Cheng KH, Berger JH, Chu GC, Pahler J, Olson P, Hezel AF, Horner J, Lauwers GY, Hanahan D, et al. Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. *Genes & development*. 2006; 20:3130–3146. [PubMed: 17114584]
- Bialkowska AB, Liu Y, Nandan MO, Yang VW. A colon cancer-derived mutant of Kruppel-like factor 5 (KLF5) is resistant to degradation by glycogen synthase kinase 3beta (GSK3beta) and the E3 ubiquitin ligase F-box and WD repeat domain-containing 7alpha (FBW7alpha). *The Journal of biological chemistry*. 2014; 289:5997–6005. [PubMed: 24398687]
- Boj SF, Hwang CI, Baker LA, Chio II, Engle DD, Corbo V, Jager M, Ponz-Sarvise M, Tiriach H, Spector MS, et al. Organoid models of human and mouse ductal pancreatic cancer. *Cell*. 2015; 160:324–338. [PubMed: 25557080]
- Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S, Brabletz T. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. *EMBO reports*. 2008; 9:582–589. [PubMed: 18483486]
- Campos FG, Figueiredo MN, Martinez CA. Colorectal cancer risk in hamartomatous polyposis syndromes. *World J Gastrointest Surg*. 2015; 7:25–32. [PubMed: 25848489]
- Chen RH, Su YH, Chuang RL, Chang TY. Suppression of transforming growth factor-beta-induced apoptosis through a phosphatidylinositol 3-kinase/Akt-dependent pathway. *Oncogene*. 1998; 17:1959–1968. [PubMed: 9788439]
- Chia NY, Deng N, Das K, Huang D, Hu L, Zhu Y, Lim KH, Lee MH, Wu J, Sam XX, et al. Regulatory crosstalk between lineage-survival oncogenes KLF5, GATA4 and GATA6 cooperatively promotes gastric cancer development. *Gut*. 2015; 64:707–719. [PubMed: 25053715]
- Cicchini C, Filippini D, Coen S, Marchetti A, Cavallari C, Laudadio I, Spagnoli FM, Alonzi T, Tripodi M. Snail controls differentiation of hepatocytes by repressing HNF4alpha expression. *Journal of cellular physiology*. 2006; 209:230–238. [PubMed: 16826572]

- DaCosta Byfield S, Major C, Laping NJ, Roberts AB. SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7. *Molecular pharmacology*. 2004; 65:744–752. [PubMed: 14978253]
- Doulatov S, Vo LT, Chou SS, Kim PG, Arora N, Li H, Hadland BK, Bernstein ID, Collins JJ, Zon LI, et al. Induction of multipotential hematopoietic progenitors from human pluripotent stem cells via respecification of lineage-restricted precursors. *Cell stem cell*. 2013; 13:459–470. [PubMed: 24094326]
- Duda DG, Sunamura M, Lefter LP, Furukawa T, Yokoyama T, Yatsuoka T, Abe T, Inoue H, Motoi F, Egawa S, et al. Restoration of SMAD4 by gene therapy reverses the invasive phenotype in pancreatic adenocarcinoma cells. *Oncogene*. 2003; 22:6857–6864. [PubMed: 14534532]
- ENCODE. An integrated encyclopedia of DNA elements in the human genome. *Nature*. 2012; 489:57–74. [PubMed: 22955616]
- Fellmann C, Hoffmann T, Sridhar V, Hopfgartner B, Muhar M, Roth M, Lai DY, Barbosa IA, Kwon JS, Guan Y, et al. An optimized microRNA backbone for effective single-copy RNAi. *Cell reports*. 2013; 5:1704–1713. [PubMed: 24332856]
- Friess H, Yamanaka Y, Buchler M, Ebert M, Beger HG, Gold LI, Korc M. Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival. *Gastroenterology*. 1993; 105:1846–1856. [PubMed: 8253361]
- Gaarenstroom T, Hill CS. TGF-beta signaling to chromatin: how Smads regulate transcription during self-renewal and differentiation. *Seminars in cell & developmental biology*. 2014; 32:107–118. [PubMed: 24503509]
- Gal A, Sjoblom T, Fedorova L, Imreh S, Beug H, Moustakas A. Sustained TGF beta exposure suppresses Smad and non-Smad signalling in mammary epithelial cells, leading to EMT and inhibition of growth arrest and apoptosis. *Oncogene*. 2008; 27:1218–1230. [PubMed: 17724470]
- Garraway LA, Sellers WR. Lineage dependency and lineage-survival oncogenes in human cancer. *Nature reviews Cancer*. 2006; 6:593–602. [PubMed: 16862190]
- Ghaleb AM, Nandan MO, Chanchevalap S, Dalton WB, Hisamuddin IM, Yang VW. Kruppel-like factors 4 and 5: the yin and yang regulators of cellular proliferation. *Cell research*. 2005; 15:92–96. [PubMed: 15740636]
- Goggins M, Shekher M, Turnacioglu K, Yeo CJ, Hruban RH, Kern SE. Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas. *Cancer research*. 1998; 58:5329–5332. [PubMed: 9850059]
- Guasch G, Schober M, Pasolli HA, Conn EB, Polak L, Fuchs E. Loss of TGFbeta signaling destabilizes homeostasis and promotes squamous cell carcinomas in stratified epithelia. *Cancer cell*. 2007; 12:313–327. [PubMed: 17936557]
- Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. *Science*. 1996; 271:350–353. [PubMed: 8553070]
- Heldin CH, Vanlandewijck M, Moustakas A. Regulation of EMT by TGFbeta in cancer. *FEBS letters*. 2012; 586:1959–1970. [PubMed: 22710176]
- Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA, Ross S, Conrads TP, Veenstra TD, Hitt BA, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. *Cancer cell*. 2003; 4:437–450. [PubMed: 14706336]
- Hingorani SR, Wang L, Multani AS, Combs C, Deramandt TB, Hruban RH, Rustgi AK, Chang S, Tuveson DA. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. *Cancer cell*. 2005; 7:469–483. [PubMed: 15894267]
- Horiguchi K, Shirakihara T, Nakano A, Imamura T, Miyazono K, Saitoh M. Role of Ras signaling in the induction of snail by transforming growth factor-beta. *The Journal of biological chemistry*. 2009; 284:245–253. [PubMed: 19010789]
- Howe JR, Roth S, Ringold JC, Summers RW, Jarvinen HJ, Sistonen P, Tomlinson IP, Houlston RS, Bevan S, Mitros FA, et al. Mutations in the SMAD4/DPC4 gene in juvenile polyposis. *Science*. 1998; 280:1086–1088. [PubMed: 9582123]

- Iacobuzio-Donahue CA, Fu B, Yachida S, Luo M, Abe H, Henderson CM, Vilardell F, Wang Z, Keller JW, Banerjee P, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology*. 2009; 27:1806–1813. [PubMed: 19273710]
- Ikushima H, Todo T, Ino Y, Takahashi M, Miyazawa K, Miyazono K. Autocrine TGF-beta signaling maintains tumorigenicity of glioma-initiating cells through Sry-related HMG-box factors. *Cell stem cell*. 2009; 5:504–514. [PubMed: 19896441]
- Kane JR, Laskin WB, Matkowskyj KA, Villa C, Yeldandi AV. Sarcomatoid (spindle cell) carcinoma of the pancreas: A case report and review of the literature. *Oncology letters*. 2014; 7:245–249. [PubMed: 24348857]
- Kim SK, Hebrok M, Li E, Oh SP, Schrewe H, Harmon EB, Lee JS, Melton DA. Activin receptor patterning of foregut organogenesis. *Genes & development*. 2000; 14:1866–1871. [PubMed: 10921901]
- Konturek PC, Dembinski A, Warzecha Z, Ihlm A, Ceranowicz P, Konturek SJ, Stachura J, Hahn EG. Comparison of epidermal growth factor and transforming growth factor-beta1 expression in hormone-induced acute pancreatitis in rats. *Digestion*. 1998; 59:110–119. [PubMed: 9586822]
- Lee TI, Young RA. Transcriptional regulation and its misregulation in disease. *Cell*. 2013; 152:1237–1251. [PubMed: 23498934]
- Li A, Omura N, Hong SM, Vincent A, Walter K, Griffith M, Borges M, Goggins M. Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a/200b in association with elevated circulating miR-200a and miR-200b levels. *Cancer research*. 2010; 70:5226–5237. [PubMed: 20551052]
- Lonardo E, Hermann PC, Mueller MT, Huber S, Balic A, Miranda-Lorenzo I, Zagorac S, Alcalá S, Rodríguez-Arabaolaza I, Ramirez JC, et al. Nodal/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy. *Cell stem cell*. 2011; 9:433–446. [PubMed: 22056140]
- Massagué J. TGFbeta in Cancer. *Cell*. 2008; 134:215–230. [PubMed: 18662538]
- Massagué J. TGFbeta signalling in context. *Nature reviews Molecular cell biology*. 2012; 13:616–630. [PubMed: 22992590]
- Morris, JPT; Cano, DA.; Sekine, S.; Wang, SC.; Hebrok, M. Beta-catenin blocks Kras-dependent reprogramming of acini into pancreatic cancer precursor lesions in mice. *The Journal of clinical investigation*. 2010; 120:508–520. [PubMed: 20071774]
- Nakaya T, Ogawa S, Manabe I, Tanaka M, Sanada M, Sato T, Taketo MM, Nakao K, Clevers H, Fukayama M, et al. KLF5 regulates the integrity and oncogenicity of intestinal stem cells. *Cancer research*. 2014; 74:2882–2891. [PubMed: 24626089]
- Nandan MO, Ghaleb AM, Bialkowska AB, Yang VW. Kruppel-like factor 5 is essential for proliferation and survival of mouse intestinal epithelial stem cells. *Stem cell research*. 2015; 14:10–19. [PubMed: 25460247]
- Ohnishi S, Laub F, Matsumoto N, Asaka M, Ramirez F, Yoshida T, Terada M. Developmental expression of the mouse gene coding for the Kruppel-like transcription factor KLF5. *Developmental dynamics: an official publication of the American Association of Anatomists*. 2000; 217:421–429. [PubMed: 10767086]
- Oshimori N, Fuchs E. The harmonies played by TGF-beta in stem cell biology. *Cell stem cell*. 2012; 11:751–764. [PubMed: 23217421]
- Oshimori N, Oristian D, Fuchs E. TGF-beta promotes heterogeneity and drug resistance in squamous cell carcinoma. *Cell*. 2015; 160:963–976. [PubMed: 25723170]
- Peinado H, Quintanilla M, Cano A. Transforming growth factor beta-1 induces snail transcription factor in epithelial cell lines: mechanisms for epithelial mesenchymal transitions. *The Journal of biological chemistry*. 2003; 278:21113–21123. [PubMed: 12665527]
- Pinon JD, Labi V, Egle A, Villunger A. Bim and Bmf in tissue homeostasis and malignant disease. *Oncogene*. 2008; 27(Suppl 1):S41–52. [PubMed: 19641506]
- Ramachandra M, Atencio I, Rahman A, Vaillancourt M, Zou A, Avanzini J, Wills K, Bookstein R, Shabram P. Restoration of transforming growth factor Beta signaling by functional expression of smad4 induces anoikis. *Cancer research*. 2002; 62:6045–6051. [PubMed: 12414627]




- Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister F, Reichert M, Beatty GL, Rustgi AK, Vonderheide RH, et al. EMT and dissemination precede pancreatic tumor formation. *Cell*. 2012; 148:349–361. [PubMed: 22265420]
- Saborowski M, Saborowski A, Morris JPt, Bosbach B, Dow LE, Pelletier J, Klimstra DS, Lowe SW. A modular and flexible ESC-based mouse model of pancreatic cancer. *Genes & development*. 2014; 28:85–97. [PubMed: 24395249]
- Stepanenko AA, Vassetzky YS, Kavsan VM. Antagonistic functional duality of cancer genes. *Gene*. 2013; 529:199–207. [PubMed: 23933273]
- Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. *Cell*. 2009; 139:871–890. [PubMed: 19945376]
- Tiwari N, Meyer-Schaller N, Arnold P, Antoniadis H, Pachkov M, van Nimwegen E, Christofori G. Klf4 is a transcriptional regulator of genes critical for EMT, including Jnk1 (Mapk8). *PloS one*. 2013a; 8:e57329. [PubMed: 23451207]
- Tiwari N, Tiwari VK, Waldmeier L, Balwierz PJ, Arnold P, Pachkov M, Meyer-Schaller N, Schubeler D, van Nimwegen E, Christofori G. Sox4 is a master regulator of epithelial-mesenchymal transition by controlling Ezh2 expression and epigenetic reprogramming. *Cancer cell*. 2013b; 23:768–783. [PubMed: 23764001]
- Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. *Cell*. 2011; 147:275–292. [PubMed: 22000009]
- Vervoort SJ, van Boxtel R, Coffey PJ. The role of SRY-related HMG box transcription factor 4 (SOX4) in tumorigenesis and metastasis: friend or foe? *Oncogene*. 2013; 32:3397–3409. [PubMed: 23246969]
- Vincent T, Neve EP, Johnson JR, Kukalev A, Rojo F, Albanell J, Pietras K, Virtanen I, Philipson L, Leopold PL, et al. A SNAIL1-SMAD3/4 transcriptional repressor complex promotes TGF-beta mediated epithelial-mesenchymal transition. *Nature cell biology*. 2009; 11:943–950. [PubMed: 19597490]
- Wagner M, Kleeff J, Friess H, Buchler MW, Korc M. Enhanced expression of the type II transforming growth factor-beta receptor is associated with decreased survival in human pancreatic cancer. *Pancreas*. 1999; 19:370–376. [PubMed: 10547197]
- Whyte WA, Orlando DA, Hnisz D, Abraham BJ, Lin CY, Kagey MH, Rahl PB, Lee TI, Young RA. Master transcription factors and mediator establish super-enhancers at key cell identity genes. *Cell*. 2013; 153:307–319. [PubMed: 23582322]
- Wiater E, Vale W. Roles of activin family in pancreatic development and homeostasis. *Molecular and cellular endocrinology*. 2012; 359:23–29. [PubMed: 22406274]
- Wilson ME, Yang KY, Kalousova A, Lau J, Kosaka Y, Lynn FC, Wang J, Mrejen C, Episkopou V, Clevers HC, et al. The HMG box transcription factor Sox4 contributes to the development of the endocrine pancreas. *Diabetes*. 2005; 54:3402–3409. [PubMed: 16306355]
- Zhang B, Zhang Z, Xia S, Xing C, Ci X, Li X, Zhao R, Tian S, Ma G, Zhu Z, et al. KLF5 activates microRNA 200 transcription to maintain epithelial characteristics and prevent induced epithelial-mesenchymal transition in epithelial cells. *Molecular and cellular biology*. 2013a; 33:4919–4935. [PubMed: 24126055]
- Zhang H, Alberich-Jorda M, Amabile G, Yang H, Staber PB, Di Ruscio A, Welner RS, Ebraldidze A, Zhang J, Levantini E, et al. Sox4 is a key oncogenic target in C/EBPalpha mutant acute myeloid leukemia. *Cancer cell*. 2013b; 24:575–588. [PubMed: 24183681]
- Zheng X, Carstens JL, Kim J, Scheible M, Kaye J, Sugimoto H, Wu CC, LeBleu VS, Kalluri R. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. *Nature*. 2015; 527:525–530. [PubMed: 26560028]
- Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, Magoon D, Qi J, Blatt K, Wunderlich M, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. *Nature*. 2011; 478:524–528. [PubMed: 21814200]



**Figure 1. TGF- $\beta$  induces EMT followed by apoptosis in the premalignant pancreas**

(A) Experimental scheme to model TGF- $\beta$ -mediated tumor suppression by re-expression of Smad4 in Smad4-mutant PDA. (B) Immunohistochemistry (IHC) for cleaved Caspase 3 (CC3) in KC or KSC pancreata collected two days after caerulein treatment, quantification at right. Scale bars 100  $\mu$ m. (C) H&E staining of a representative KSIC autochthonous tumor (top) and orthotopic tumor (bottom). Scale bars 200  $\mu$ m. (D) Representative H&E staining and GFP/E-cadherin immunofluorescence after orthotopic injections of the indicated cells, collected 3.5 days post-injection. Apoptotic cells are indicated with arrows

(see high magnification inset, Smad4+ H&E section.) Scale bars 50  $\mu$ m. **(E)** Cells grown in monolayer in high serum medium containing 2.5  $\mu$ M MK2206 were treated with TGF- $\beta$  (100 pM) or SB505124 (SB; 2.5  $\mu$ M) and assayed for cleaved Caspase 3/7 activity at the indicated times. **(F)** Time lapse microscopy of Smad4+ cells at the indicated times following TGF- $\beta$  treatment (see also Supplementary Video 1). **(G)** Immunoblot of EMT marker E-cadherin (E-cad) and apoptosis marker cleaved Caspase 3 (CC3) after TGF- $\beta$  treatment. **(H)** Pancreatic organoids cultured from KIC or KSIC mice were treated with MK2206 and TGF- $\beta$  or SB505124, and were assayed for cleaved Caspase 3/7 activity at the indicated times. **(I)** 3-dimensional images of E-cadherin and CC3 immunofluorescence performed in KIC or KSIC PDA organoids treated as indicated for 24 h. Scale bars 10  $\mu$ m. Values in panels E and H are results of 3 biological replicates. Bar graphs represent mean  $\pm$  SD.




**Figure 2. Snail and Zeb1 promote EMT and apoptosis**

(A). List of most strongly induced genes after 90 min of TGF $\beta$  treatment in Smad4+ cells. (B) Immunoblot for Snail and Zeb1 in Smad4-mutant and Smad4+ cells after 24 h of TGF $\beta$ . (C) Smad2/3 binding to the *Snai1* locus after 1 h of TGF $\beta$  treatment in Smad4-mutant or Smad4+ cells. (D) Immunoblot for E-cadherin in Smad4+ cells expressing the indicated shRNAs 24 h post-TGF $\beta$ /SB treatment. (E) Images of Smad4+ cells treated with TGF $\beta$  for 72h expressing control shRNAs, or shRNAs targeting *Snail* or *Zeb1*. (F) Smad4+ cells expressing *Snai1*-targeting (left panel) or *Zeb1*-targeting shRNAs (right panel) were treated

with TGF $\beta$  or SB for 36 h then assayed for Caspase 3/7 activity. **(G)** Smad4+ cells transduced with Tet-On Snail were treated with or without dox for 12 h followed by TGF- $\beta$  or SB, then assayed for caspase activity after 18 h. **(H)** H&E and CK19 IHC for representative ADM or atypical ADM lesions in KC or KSnSnC mice. Scale bars 100  $\mu$ m. Values in panels F and G are the average of 3 biological replicates. Bar graphs represent mean  $\pm$  SD.






**Figure 3. Sox4 is required for TGF- $\beta$ -driven apoptosis**

(A) Experimental scheme to screen for factors required for TGF- $\beta$ -induced cell death. (B) Plot depicting shRNA enrichment/depletion in TGF- $\beta$  vs SB treated cells. Positive control shRNAs targeting *Tgfb1* and *Tgfb2* and negative control shRNAs targeting Renilla luciferase are indicated. See also Table S2. (C) Indicated TetOn Sox4 shRNAs were transduced into Smad4+ cells, cells were pre-treated with or without dox for 24 h, then treated as indicated. Caspase activity was assayed after 36 h. (D) Images of control or Sox4 KD cells treated with TGF- $\beta$  for 37 h (see also Supplementary Video 2). (E) Immunoblot for the indicated factors after Sox4 depletion and 24 h of SB/TGF $\beta$  treatment. (F) Sox4 immunoblot after 24 h of TGF $\beta$  treatment in cells bearing control shRNAs or shRNAs



targeting the *Snail* or *Zeb1* transcripts. Samples and load control same as Figure 2D. **(G)** Publicly available RNA-seq expression data from The Cancer Genome Atlas (TCGA) derived from 179 PDA tumors was used to plot *SOX4* and *CDH1* levels. Spearman and Pearson correlation coefficients are indicated. **(H)** TetOn Sox4 Smad4+ PDA cells were treated as indicated and assayed for apoptosis after 18 h. Values in panels C and H are averages of 2 and 3 biological replicates, respectively. Bar graphs represent mean  $\pm$  SD.



**Figure 4. Sox4 is part of a Smad4-independent group of TGF-β-induced genes**

(A) Sox4 mRNA levels in the indicated cells after 24 h of the indicated treatment. Values are the mean and range of four technical replicates, and representative of at least 3 separate experiments. (B) Immunoblot for Sox4 after 24 h of the indicated treatment in mPDA (top) and BxPC3 cells (bottom). (C) Immunohistochemistry for Sox4 performed 72 h after Smad4(-) or Smad4(+) PDA cells were implanted in the pancreata of syngeneic mice. Inset shows higher magnification image of Sox4+ EMT cancer cell. (D) Smad4 dependence of 90-minute TGF-β genes. Fold induction in Smad4-mutant and Smad4+ cells is plotted on the x- and y-axes respectively. Select Smad4-independent genes were assayed by qRT-PCR after 12 h induction and plotted (red-shaded region). (E) Smad2/3 binding to the Sox4 locus as determined by ChIP-seq performed in Smad4-mutant and Smad4(+) cells. (F) Summary


diagram showing cooperation between Smad4-dependent and Smad4-independent branches to induce apoptosis.

Author Manuscript

Author Manuscript

Author Manuscript


Author Manuscript



**Figure 5. Sox4 plays a pro-tumorigenic role in PDA cells**

(A) Experimental scheme for identification of tumorigenic transcription factors in PDA. (B) Waterfall plot depicting results of an shRNA screen of the 93 most highly expressed TFs in PDA cells. Cells expressing the library were grown as oncospheres for 18 days with one passage. Data presented is the merged results of two separate pools. See also Table S3. (C) PDA cells expressing the indicated shRNAs were plated as oncospheres and counted after one week. (D) Bright-field images of cells expressing a control or Sox4 shRNA grown as oncospheres for 2 weeks. Scale bar 200  $\mu$ m. (E) PDA cells transduced with a TetOn Sox4

shRNA were cultured in full serum medium in 2 dimensional culture, and were assayed for cell viability at the indicated times (in h). **(F)** Tumor-free survival after KSIC mPDA cells transduced with TetOn Sox4 shRNAs were injected subcutaneously into mice maintained on or off dox diet. Plot reflects results of pooled experiments using Sox4.965 and Sox4.2509 shRNAs. For each condition (on or off dox), n = 10 mice, survival compared by log-rank test. **(G)** Luciferase labeled KSIC cells transduced with the indicated shRNAs were injected orthotopically in mice and imaged after four weeks. Luminescence was normalized to day 0 values. Statistical significance was calculated by a two-tailed unpaired t test. **(H)** Sox4 protein expression after SB/TGF- $\beta$  treatment of cells grown in adherent conditions (right) or after three days in oncosphere conditions (left). **(I)** Secondary oncosphere formation of Smad4-mutant and Smad4+ PDA cells. Primary oncospheres were cultured for two weeks in the presence or absence of 20 pM TGF- $\beta$ . Spheres were dissociated by trypsinization and replated for one week prior to counting. Values in panels C and I are the average of 3 biological replicates. Bar graphs represent mean  $\pm$  SD.




**Figure 6. Klf5 is a lineage survival gene that determines Sox4 function**

(A) KSIC mPDA cells transduced with TetOn Klf5 shRNAs were grown as oncospheres for two weeks as indicated then quantified. (B) KSIC cells were transduced with the indicated shRNAs and implanted orthotopically in mice maintained on doxycycline feed. Mice were imaged after four weeks. Control group same as Figure 5G. (C) Heatmap showing highly expressed TFs in cancer exhibiting lineage specificity. TCGA RNA-seq data was used to rank TFs by average expression levels in the indicated tumor types. To identify lineage specific TFs, we included any TF with expression in the top 0.5% in at least one tumor type,



while excluding TFs that exhibited expression in the top 10% in more than half of the tumor types analyzed. The latter step excluded 22 TFs. Tumor types exhibiting >10% of loss of TGF- $\beta$  signaling are indicated in red. **(D)** Heatmap showing overlap between Sox4, Klf5, and Med1 ChIP-seq peaks. Below is a venn diagram depicting overlap between Sox4 and Klf5 ChIP-seq peaks **(E)** Smad4-mutant PDA cells transduced with the indicated TetOn shRNAs were treated with dox for 48 h to deplete the target protein, followed by treatment with SB/TGF- $\beta$ . Cells were assayed for Caspase 3/7 activity after 36 h SB/TGF- $\beta$  treatment. **(F)** A TetOn Klf5 construct was introduced into constitutive Smad4(+) cells. Klf5 was induced with doxycycline for 12 hours prior to the addition of MK2206. Cells were then treated with SB/TGF- $\beta$  for 36 h, and assayed for caspase 3/7 activity. **(G)** TetOn Klf5 cells were treated as in (F), then immunoblotted after 24 h of the indicated treatment. **(H)** 3000 Smad4(+) TetOn Klf5 cells were injected orthotopically in caerulein-treated mouse pancreata. Mice were sacrificed after 2 weeks, and pancreata subjected to serial sectioning and quantification of maximal tumor surface area, plotted as indicated (On dox n=14, Off dox n=10; unpaired two-tailed t test). **(I)** Klf5.1343 shRNA was cloned into a tandem TetOn shRNA vector together with shRNAs targeting Renilla luciferase or Sox4. Cells were incubated with dox for 48 h, then treated as indicated and assayed for Caspase 3/7 activity after 36 h. Values in panels A, E, F, and I are the average of 3 biological replicates. SD and p values were calculated by a two-tailed t test.



**Figure 7. EMT-linked Klf5 repression promotes an apoptotic Sox4 program**

(A) Immunoblot for highly expressed endoderm-associated TFs after 24 h of the indicated treatment. (B) The indicated cells were injected as in Figure 1D. Klf5 and GFP were then detected by immunofluorescence. Scale bars 50 μm. (C) Smad2/3 ChIP-qRT-PCR performed at the indicated loci in the presence of control, or Snail/Zeb1 shRNAs. Error bars represent the mean and range of 4 technical replicates, representative of two separate experiments. Cells were treated with SB/TGF-β for 12 h prior to crosslinking. (D) Sox4-dependent gene expression in TGF-β-treated Smad4+ cells. Cells bearing TetOn Sox4

shRNAs were cultured  $\pm$  dox for 24 h prior to treatment with TGF- $\beta$ . After another 24 h, RNA was extracted and RNA-seq was performed. Sox4-dependent differentially expressed genes were then plotted. **(E)** qRT-PCR validation of Bim and Bmf as Sox4-dependent gene responses in TGF- $\beta$ -treated Smad4+ cells. Values are the result of 4 technical replicates. **(F)** Diagram summarizing effects of TGF- $\beta$  signaling in naïve PDA cells.